Skip to main content
News and Events banner photo

News & Events
Stay Informed with Industry Insights and Follow Our Progress

Scientist in background holding filled vial in foreground

Filter

Company News

Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

JIANGSU, China, August 22, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…
August 22, 2024
Company News

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

JIANGSU, China, July 25, 2024 -- Ractigen Therapeutics, a pioneering developer of small activating RNA…
July 25, 2024
Company NewsRAG-01

Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

SUZHOU, China, May 21, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…
May 21, 2024
Company NewsRAG-17

Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

JIANGSU, CHINA (May 15, 2024) – Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing…
May 15, 2024
Company NewsRAG-01

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…
April 26, 2024
Company NewsRAG-01

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…
April 3, 2024
Close Menu